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Abstract
Background: Neuroinflammation is a key phenomenon in the pathogenesis of many neurodegenerative diseases.
Understanding the mechanisms by which brain inflammation is engaged and delineating the key players in the
immune response and their contribution to brain pathology is of great importance for the identification of novel
therapeutic targets for these devastating diseases. Gaucher disease, the most common lysosomal storage disease,
is caused by mutations in the GBA1 gene and is a significant risk factor for Parkinson’s disease; in some forms of
Gaucher disease, neuroinflammation is observed.
Methods: An unbiased gene profile analysis was performed on a severely affected brain area of a neurological
form of a Gaucher disease mouse at a pre-symptomatic stage; the mouse used for this study, the Gbaflox/flox;
nestin-Cre mouse, was engineered such that GBA1 deficiency is restricted to cells of neuronal lineage, i.e.,
neurons and macroglia.
Results: The 10 most up-regulated genes in the ventral posteromedial/posterolateral region of the thalamus were
inflammatory genes, with the gene expression signature significantly enriched in interferon signaling genes.
Interferon β levels were elevated in neurons, and interferon-stimulated genes were elevated mainly in microglia.
Interferon signaling pathways were elevated to a small extent in the brain of another lysosomal storage disease
mouse model, Krabbe disease, but not in Niemann-Pick C or Sandhoff mouse brain. Ablation of the type I interferon
receptor attenuated neuroinflammation but had no effect on GD mouse viability.
Conclusions: Our results imply that the type I interferon response is involved in the development of nGD pathology,
and possibly in other lysosomal storage diseases in which simple glycosphingolipids accumulate, and support the
notion that interferon signaling pathways play a vital role in the sterile inflammation that often occurs during chronic
neurodegenerative diseases in which neuroinflammation is present.
Background
Type I interferons (IFNs; Ifnα1-13 and Ifnβ), a large family
of structurally related cytokines, are key components of
the innate immune response and are the fundamental cel-
lular defense mechanism against viral infection [1]. IFNs
are currently used therapeutically for a number of viral
diseases, for numerous malignancies, and for a number of
chronic inflammatory disorders such as the demyelinating
disease and multiple sclerosis [2]. However, even though
activation of the type 1 IFN response has been intensely
studied as part of the host response to viral and bacterial
infection, induction of this response has also been
observed in the absence of infection [3]. In the central
nervous system (CNS), IFN activation occurs in amyo-
trophic lateral sclerosis (ALS) [4], in Alzheimer’s disease
(AD) [5], during aging [6], in Aicardi-Goutières syndrome
(AGS) [7, 8], and upon axonal transection [9]. Activation
of the IFN response under sterile conditions has led to a
paradigm shift in our understanding of the role of these
cytokines and their role in inflammation inasmuch as the
type I interferonopathies are now believed to comprise a
heterogeneous group of genetically determined diseases
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A wide range of neurodegenerative conditions are char-
acterized by brain inflammation, including Alzheimer’s
and Parkinson’s diseases (PD) [11], and the less common
lysosomal storage diseases (LSDs) [12–14], which are
normally caused by the defective activity of a lysosomal
hydrolase. One such LSD is Gaucher disease (GD), caused
by mutations in the GBA1 gene, which encodes the
lysosomal enzyme, acid-β-glucosidase (glucocerebrosidase,
GCase) [15], resulting in the accumulation of the sphingo-
lipid glucosylceramide (GlcCer) and its deacylated form,
glucosylsphingosine (GlcSph) [16, 17]. GD is the most
common LSD and ~10 % of GD patients worldwide
present with neurological symptoms. However, the dis-
tinction between neurological and non-neurological forms
of the disease has become blurred over the recent years
based on the finding that heterozygous mutations in
GBA1 are a major risk factor for PD [18]. Thus, under-
standing the pathological pathways activated upon alter-
ation of GCase activity in the brain might have significant
ramifications for understanding more common neurode-
generative diseases such as PD.
The neuronopathic forms of GD, types 2 and 3, are
characterized by astrogliosis, neuronophagia (i.e., brain
inflammation), and neuronal loss [19, 20]. We now
demonstrate elevation of IFNβ levels in neurons and
activation of the type 1 IFN response in mouse models of
neuronopathic Gaucher disease (nGD), but to a much
lower extent, or absent completely, in other LSD mouse
models. This discovery was made during an unbiased
gene profile analysis of a severely affected brain area of an
nGD mouse at a pre-symptomatic stage. The mouse used
for this study, the Gbaflox/flox; nestin-Cre mouse [21], was
engineered such that GBA1 deficiency is restricted to cells
of neuronal lineage, i.e., neurons and macroglia. Robust
induction of type I IFN-stimulated genes (ISGs), including
pathogen recognition receptors (PRRs) and antiviral genes
was observed; the lack of activation of this pathway in
other LSDs suggests that GlcCer and/or GlcSph specific-
ally activate the antiviral response. Moreover, our data
suggest that a key player in the pathway of programmed
necrosis, the protein mixed lineage kinase domain-like
(MLKL), is a novel ISG which is induced down-stream to
the IFN receptor in cells of myeloid lineage. Together,
our data demonstrate that the IFN response can be acti-
vated in neuroinflammation under sterile conditions and
that this pathway might be involved in nGD pathogenesis,
although whether this pathways is detrimental or benefi-
cial remains to be established.
Results
Induction of the type I interferon response
To determine changes in gene expression in the brain of
the Gbaflox/flox; nestin-Cre mouse, herein referred to as
the Gba−/− mouse, we performed a microarray analysis on
the ventral posteromedial/posterolateral (VPM/VPL) re-
gion of the thalamus, the area which is most affected in
the Gba−/− mouse, at 14 days of age, an age at which the
first signs of neuroinflammation and neuronal loss are
observed but prior to overt signs of disease [22].
Approximately 10 % of the genes detected by the array
were differentially expressed (absolute fold-change ≥1.5,
p value ≤0.05), with 907 genes up-regulated in Gba−/−
versus Gba+/− mice and 481 genes down-regulated (for
a complete list of the differentially-expressed
transcripts, see Additional file 1: Table S1). Changes in
expression of Gfap, Lgals3, Kcnk4, Sptssb, and Ryr3
were confirmed by quantitative polymerase chain
reaction (qPCR) using the same RNA samples used for
the microarray analysis, and their fold-changes were
~100, ~230, ~0.35, ~0.35, and ~0.40, respectively. Up-
regulated genes were next subjected to gene ontology
(GO) analysis [23] (Fig. 1a). Among the up-regulated
genes, innate immune response pathways, and surpris-
ingly, type I IFN-related pathways, were highly enriched
(Fig. 1a). The robust induction of the immune response,
and in particular of the type I IFN response, was con-
firmed by the fact that the 10 most up-regulated genes
were all genes that are induced during neuroinflamma-
tion, with most induced by type I IFN (Table 1).
Gene set enrichment analysis (GSEA) confirmed that
the gene expression signature of the Gba−/− mouse was
significantly enriched in IFN signaling genes, with an ap-
proximate false discovery rate of zero and a normalized
enrichment score of 2.27 (Fig. 1b, c). Innate immunity is
the first line of defense against infection and cell damage
and is triggered by the recognition of pathogen/danger-as-
sociated molecular patterns (PAMPs or DAMPs) by PRRs.
Genes encoding various PRRs were elevated in the Gba−/−
brain, including Toll-like receptors (Tlr), which encode
transmembrane PRRs, other membrane-bound PRRs such
as the C-type lectin receptors, Clec7a (Dectin-1) and
Clec5a (MDL-1) [24], and the scavenger receptors Cd36
and Msr1 (SR-A1) [25] (Additional file 1: Table S1). Genes
encoding cytosolic nucleic-acid sensing PRRs [26] were
also up-regulated (Additional file 1: Table S1). PRR stimu-
lation leads to IFN transcription and secretion [27] by
interferon regulatory factor (IRF) transcription factors
[28], of which Irf7, Irf8, Irf9, Irf1, and Irf5 were up-
regulated. Irf7, which is among the most highly-elevated
genes (Table 1), is the master regulator of type I IFN sig-
naling, and its expression is further up-regulated by type I
IFN [29]. qPCR analysis confirmed that Irf7 was highly in-
duced in the VPM/VPL of Gba−/− mice (Fig. 1d). Both
Ifnb1 and Ifna2 mRNA levels were also elevated (~20 and
~2-fold, respectively) in the cerebral cortex of Gba−/− mice
(Fig. 1d), another highly affected brain area in nGD mice
[22]. Moreover, IFNα and IFNβ were detected by enzyme-
linked immunosorbent assay (ELISA) in cerebral tissue
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from Gba−/− mice, but not from control mice (Fig. 1e).
Crucially, levels of IFNβ were also elevated in the two avail-
able cerebella of human patients who succumbed to type 2
GD (Fig. 1e).
IFNα and IFNβ bind the Ifnα/β receptor (IFNAR) to
induces gene expression via the Janus kinase (JAK)-sig-
nal transducer and activator of transcription (STAT)
pathway, resulting in expression of a large spectrum of
ISGs [27]. Phosphorylated Stat2 was up-regulated in an
affected Gba−/− brain area (Fig. 2a), and its levels were
increased in both MAC2-positive (i.e. activated micro-
glia/macrophages) and MAC2-negative cells (Fig. 2a).
P-Stat2 rarely co-localized with the neuronal nuclear
marker NeuN, but neuronal cell bodies were frequently
encircled by P-Stat2 staining, likely indicating P-Stat2 ele-
vation in phagocytic cells (Fig. 2a). Finally, P-Stat2 staining
Fig. 1 Activation of the type I IFN response in nGD. a The 10 most significantly enriched GO terms for up-regulated genes illustrating enrichment
of type I IFN-related pathways. The plot shows the enrichment p values. The number of differentially expressed genes out of the total number of
genes included in the term detected by the array are indicated. n = 3, 14-day-old mice. b, c Gene set enrichment analysis (GSEA) of gene expression in
Gba−/−compared to Gba+/– mice. b GSEA enrichment plot. False discovery rate (FDR) q value; normalized enrichment scores (NES). c Heat map
displaying the relative expression level of proteins in the interferon signaling set, sorted by their fold change. Depicted are the top 51 genes. d qPCR
analysis of Irf7 mRNA in the VPM/VPL obtained from 16-day-old mice and of Ifnb1 and Ifna2 mRNA in cortical tissues obtained from 21-day-old mice.
**p < 0.001, *p < 0.005. Values are shown as fold change in mRNA levels (Gba−/− versus control) and are means ± s.e.m, n = 3–4. e ELISA analysis of IFNα
and IFNβ protein levels in cerebral brain tissue obtained from 21-day-old control and Gba−/− mice. IFNα and IFNβ were not detected in control
samples. *p< 0.005. Values are means ± s.e.m, n= 3 (upper panel). IFNβ protein levels in cerebellum of two human type 2 GD patients (n= 2) compared
to age-matched control brains (n= 4). p value = 0.06 (lower panel)
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was also detected in the nuclei of cells that were not
labeled with the neuronal marker, NeuN (Fig. 2a).
A number of ISGs down-stream to JAK-STAT [30]
were up-regulated, indicating activation of IFNAR and
the antiviral response (Fig. 2b). Isg15, which mediates
IFN-regulated ubiquitination of cellular and viral targets
termed ISGylation [1], was up-regulated (Fig. 2b), as
were genes encoding proteins which sequentially
catalyze the conjugation of Isg15 to proteins [1] (Fig. 2b).
ISGylation is reversible, and Usp18, a negative regulator
of type I IFN signaling which catalyzes the hydrolysis of
Isg15 [30], was one of the most highly up-regulated
genes (Table 1 and Fig. 2b), consistent with a robust
activation of the type I IFN response.
The double-stranded RNA-dependent protein kinase
(PKR), encoding by the ISG [1] Eif2ak2, is a major anti-
viral effector due to its role in blocking protein synthesis
by phosphorylating the α subunit of eukaryotic translation
initiation factor 2α (eIF2α) [31]. PKR protein levels were
highly elevated in the cerebral cortex of Gba−/− mice
(Fig. 3a), confirming the microarray results (Fig. 2b). PKR
levels were also elevated in tissues from the two available
cerebella obtained from human patients who succumbed
to type 2 GD (Fig. 3b). Interestingly, PKR has recently
been shown to play a role in programmed necrosis medi-
ated by IFNs [32]. IFN induces association of PKR with
receptor-interacting protein 1 (RIP1; RIPK1) to form
assembly of the necrosome complex which contains RIP1,
RIP3, and MLKL, and to initiate programmed necrosis
and/or activation of the inflammasome; recently, we
demonstrated that RIP3 is involved in nGD pathology
[33]. PKR was selectively up-regulated in layer V of the
cortex (Fig. 3c), another brain area which displays signifi-
cant pathology in the Gba−/− mouse, and MAC2-positive
cells expressed high levels of PKR (Fig. 3c), similar to that
observed for P-Stat2 (Fig. 2a) and for RIP3 [33]. PKR also
co-localized with the astrocyte marker, GFAP (Fig. 3c).
Ablation of the type I IFN receptor attenuates
neuroinflammation but has no effect on the
viability of nGD mice
To determine the role of the IFN-I receptor (IFNAR) in
GD, IFN-I receptor-deficient (Ifnar1−/−) mice [34] were
injected with conduritol B epoxide (CBE), an irreversible
GCase inhibitor, which can be used to induce GD in
mice with different severities depending on the dose
used [35, 36]. Unlike Rip3−/− mice, which develop GD
upon CBE injection much more slowly than their
littermate controls [33], no differences in the lifespan or
in the weight of Ifnar1−/− mice were observed upon CBE
injection (Fig. 4a, b). However, the extent of elevation of
genes down-stream to IFNAR, such as Irf7, Ifnb1, and
Eif2ak2, was significantly lower in Ifnar1−/− mice injected
with CBE compared to Ifnar1+/− mice. mRNA levels of
other inflammatory markers that are elevated in nGD
mice [12, 37] (i.e., Ccl2 (MCP-1), Ccl5 (RANTES), and
glycoprotein non-metastatic B (GPNMB)) were sig-
nificantly reduced in Ifnar1−/− mice upon CBE injec-
tion (Fig. 4c), although no differences were observed
in levels of Ccl3 (MIP1α) and the astrocyte marker,
Gfap (Fig. 4c). Levels of activated microglia/macro-
phages were higher upon CBE injection in both
Ifnar1−/− and Ifnar1+/− mice (Fig. 4d), although blocking
the type I IFN response caused a small but significant de-
crease in levels of activated microglia/macrophages (Fig. 4d),
confirming a role for IFN in activation of the innate
immune response in nGD.
mRNA levels of both Rip1 and Rip3 were up-
regulated to a similar extent in both Ifnar1−/− and
Ifnar1+/− mice upon CBE injection (Fig. 4c). Interest-
ingly, mRNA levels of Mlkl, a crucial protein involved
in necroptosis induction [38] and required for activity
of the NLRP3 inflammasome, was significantly lower
in Ifnar1−/− mice injected with CBE (Fig. 4c), suggesting
thatMlkl is an ISG.
Table 1 Top ten up-regulated genes
Gene symbol Gene name Fold change (−/− vs. +/−) p value Referencea
Cxcl10* (IP-10) Chemokine (C-X-C motif) ligand 10 86.3 <0.001 [68]
Usp18* Ubiquitin specific peptidase 18 79.2 <0.005 [30]
Ifit1* Interferon-induced protein with tetratricopeptide repeats 1 75.2 <0.001 [69]
Irf7* Interferon regulatory factor 7 71.7 <0.005 [30]
Cxcl13* Chemokine (C-X-C motif) ligand 13 67.2 <0.05 [70]
Gpnmb Glycoprotein (Transmembrane) Nmb 63.0 <0.005
Lcn2 Lipcalin 2 60.1 <0.005
Oasl2* 2′-5′ oligoadenylate synthetase-like 2 56.0 <0.005 [30]
Tgm1 Transglutaminase 1, K polypeptide 46.5 <0.005
Ifit3* Interferon-induced protein with tetratricopeptide repeats 3 42.1 <0.001 [69]
Type I IFN-induced genes are indicated by asterisks
aReferences refer to studies demonstrating that these genes are induced by type I IFN
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IFNβ production in neurons that accumulate GlcCer leads
to ISG expression in neighboring microglia
To determine in which cell types IFNβ was elevated in
nGD mice, Ifnb1tm1Lky/J mice, which co-express Ifnb1
and EYFP from the Ifnb1 locus, were injected with CBE.
IFNβ immunoreactivity was significantly elevated in
layer V of the cerebral cortex of CBE-treated mice
(Fig. 5a), mainly in neurons and occasionally in micro-
glia, but no elevation was detected in astrocytes. To de-
termine the contribution of microglia to ISG expression
down-stream to IFNAR, nGD was induced by CBE
injection in Ifnarflox/flox; CX3CR1-Cre mice [39, 40],
Fig. 2 Induction of the JAK/STAT pathway in nGD. a P-Stat2 is increased in the nGD brain. Double immunofluorescence of cortical layer V
in 16-day-old mice using anti-P-Stat2 (red) and anti-MAC2 (green, upper and middle panels) or anti-NeuN (green, lower panel) antibodies and the nuclear
marker, DAPI (blue). Arrows indicate nuclear staining of P-Stat2. Scale bar, 25 μm. Results are representative of three experiments. b Microarray analysis
of ISG expression in the nGD brain. Data is presented as fold change of mRNA levels (Gba−/− versus Gba+/–). Values are means ± s.e.m, n = 3. *p < 0.05,
**p < 0.05, ***p < 0.005. Janus kinase (JAK); signal transducer and activator of transcription (STAT)
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which lack the IFN receptor in mononuclear phagocytic
cells (i.e. microglia in the brain). While mRNA levels of
Gpnmb, Rip1, and Rip3 were up-regulated to a similar
extent as in control (Ifnarflox/flox) mice upon CBE
treatment, levels of Ccl2, Ccl5, Irf7, Eif2ak2 (PKR),
Usp18, Oas1b, and Mlkl were significantly lower in
the Ifnarflox/flox; CX3CR1-Cre mice (Fig. 5b), indicat-
ing that their transcription is down-stream to IFNAR
in microglia in nGD brain.
Distinct inflammatory profiles in brains from different
LSD mouse models
Brain inflammation and microglial activation are shared
features of many LSDs [13, 14, 41–43]. Thus, we exam-
ined whether IFNs and antiviral ISGs are up-regulated in
other LSDs which present significant brain inflammation.
Expression levels of the astrocyte marker, Gfap, and the
myeloid-lineage cell marker, Adgre1 (F4/80), as well as
the inflammatory chemokines Ccl3, Ccl5, Gpnmb, Il-1β,
and Tnfα were up-regulated in cerebral hemispheres
obtained from the most severe stage of mouse models of
nGD [21], Krabbe’s disease [44], Niemann-Pick type C1
disease (NPC1) [5] and Sandhoff disease [45], indicative
of neuroinflammation (Table 2). However, levels of Ifnb1
were only significantly up-regulated in cerebral hemi-
spheres from nGD mice, and to a small extent in Krabbe
mice; no significant elevation was detected in either
NPC1 or in Sandhoff disease (Table 2), suggesting that
the antiviral response is elevated specifically in diseases in
which simple glycosphingolipids are elevated. Genes
related to the RIPK pathway were likewise only elevated
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Fig. 3 Elevation of PKR (Eif2ak2) in Gba−/− mice. a Western blot of homogenates (150 μg of protein) from the cortex of 21-day-old Gba−/− mice
(n = 5). GAPDH was used as loading control. b Western blot of homogenates (50 μg of protein) from the cerebellum of two human patients who
succumbed to type 2 GD compared to an age-matched control brain. c PKR levels in microglia/macrophages and in astrocytes in the Gba−/−
brain. Immunofluorescence of cortical layer V in 16-day-old Gba−/− using anti-PKR (green), anti-MAC2 (red), or anti-GFAP (red) antibodies. Upper
panel PKR staining is located in pathological areas as shown by staining of both MAC2 and GFAP. Scale bar, 100 μm. Middle and lower panels
Double immunofluorescence of 16-day-old Gba−/− mice using either anti-PKR and anti-MAC2 (middle panel) or anti-PKR and anti-GFAP (lower
panel) antibodies. PKR is in green, MAC2 and GFAP are in red, and areas of overlap are indicated on the right. Scale bar, 10 μm. Results are
representative of three experiments
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Discussion
Type I IFNs are mainly recognized as part of the host
response to viral and bacterial infection. Much less is
known about the role of the type I IFN response under
conditions of sterile inflammation, particularly in the
CNS [3–6]. Activation of this response in the absence of
infection can either be detrimental, as in AD, ALS, and
AGS, or beneficial, as in multiple sclerosis. Interestingly,
depletion of IFNβ causes spontaneous neurodegenera-
tion resembling sporadic Lewy body and PD [46]. In the
current study, we demonstrate massive induction of the
type I IFN response in nGD brain at a pre-symptomatic
stage, suggesting a key role for the antiviral response in
the initial stages of brain pathology.
The mechanism by which the immune response is
triggered in nGD is not known. Importantly, in the
Gbaflox/flox; nestin-Cre mouse, microglia do not accu-
mulate GlcCer [21] and their activation cannot there-
fore be due to intrinsic GlcCer accumulation, but
must rather be a response to extrinsic signals from
other cells that do accumulate GlcCer, such as neurons
and/or astrocytes. PRRs, ISGs, and other components
Fig. 4 Effect of IFNAR on nGD progression and on down-stream signaling pathways. a Body weight of Ifnar+/− (n = 12) and Ifnar−/− (n = 19) mice
treated with CBE (37.5 mg/kg per day) from 8 days of age or untreated mice (control, n = 9). Results are means ± s.e.m. b Kaplan-Meyer survival
curves for Ifnar+/− (n = 12) and Ifnar−/− (n = 19) mice. c qPCR analysis of various genes in cortical homogenates from ~30-day-old Ifnar+/− (n = 2)
and Ifnar−/− (n = 3) mice treated with CBE (37.5 mg/kg per day) from 8 days of age. Results are expressed as fold change of CBE-treated versus
control and are means ± s.e.m. CT values were normalized to levels of HPRT. *p < 0.005, **p < 0.001. d Left, Western blots of homogenates (80 μg
of protein) from cortex of ~30-day-old Ifnar+/− (+/−) and Ifnar−/− (−/−) (control) mice treated with or without CBE (+/− CBE, −/− CBE) from 8 days
of age. Blots were probed with an anti-MAC2 antibody. Results are representative of three experiments for control mice and five for CBE treated
mice. GAPDH was used as loading control. Right Densitometer analysis of the blots. *p < 0.05
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of innate immunity are expressed in astrocytes, micro-
glia, and neurons [47, 48], and our data is consistent
with the idea that the initial activation of the immune
response is up-stream to IFNAR in microglia. A
remaining challenge is to determine if the immune
response is triggered by PRRs which directly sense
increased GlcCer levels or by PRRs that sense known
PAMPs/DAMPs such as dsRNA, cytosolic DNA, glyco-
proteins, and nucleic acids, which for unknown
reasons may be altered in nGD (Fig. 6). Constitutive
up-regulation of type I IFN production was found in a
group of monogenic diseases characterized by neuro-
logical and dermatological features, known as type I
interferonopathies, which result from accumulation of
Fig. 5 Induction of the IFN response in neurons and downstream signaling in microglia. a Elevation of IFNβ in neurons in the cerebral cortex of
18-day-old CBE-treated mice (100 mg/kg, from 8 days of age) compared to untreated mice (control). Double immunofluorescence using either
anti-GFP (IFNβ, green) and anti-NeuN (red), anti-GFP and anti-MAC2 (red), or anti-GFP and anti-GFAP (red) antibodies and the nuclear marker, DAPI
(blue). Scale bar, 10 μm. Results are representative of two experiments. b qPCR analysis of various genes in cortical homogenates from 18-day-old
Ifnarflox/flox; CX3CR1-Cre + (n = 4) and Ifnarflox/flox; CX3CR1-Cre- (n = 4) mice treated with CBE (100 mg/kg per day) from 8 days of age for 10 days.
Results are expressed as fold change of CBE-treated versus control (n = 3–4) mice and are means ± s.e.m. CT values were normalized to levels of
HPRT. *p < 0.05, **p < 0.01, ***p < 0.001
Vitner et al. Journal of Neuroinflammation  (2016) 13:104 Page 8 of 15
endogenous nucleic acid products, which are subsequently
sensed as non-self by the innate immune machinery [8].
Cross-talk between changes in lipid composition and TLR
signaling was recently demonstrated, with GD fibroblasts
displaying a hyper-inflammatory response to TLR-induced
IL-6 release [49]. This, together with our data, suggests a
scenario by which GlcCer is recognized as a DAMP upon
its accumulation in nGD leading to IFN induction and
secretion. Subsequently, IFN activates surrounding micro-
glia via binding to IFNAR, resulting in the phosphoryl-
ation of STAT and induction of ISGs [27]. Neurons from
distinct brain regions have unique innate immune signa-
tures which determine their susceptibility to viral infection
[50], and we speculate that different neuronal populations
have different immunological properties which might
explain their selective vulnerability to GlcCer accumula-
tion in nGD [16] and to other lipids and/or substrates in
other LSDs.
Brain inflammation is a universal feature of many
neurodegenerative diseases, including LSDs with brain
involvement. The inflammatory response can take many
guises, being initiated in response to different stimuli,
can be chronic or acute, beneficial or detrimental, all of
which can be mediated by different inflammatory
factors. Each LSD has its own pattern of accumulation
of storage material and its own pattern of neuroinflam-
mation [42]. It is notable that of the four LSDs that we
studied, nGD gave the most severe inflammatory
response, although this might, at least in part, be due to
the rapid onset of disease symptoms in the Gbaflox/flox;
nestin-Cre mouse compared to the other mouse models
examined. The Gbaflox/flox; nestin-Cre mouse displayed
by far the most robust type 1 IFN response, as exempli-
fied by highly elevated levels of Irf7 and Usp18. Ours is
of course not the first study to examine patterns of gene
activation in the brains of LSD mice or patients, but lack
Table 2 qPCR analysis of genes in cerebral hemispheres obtained from the end-stage of various LSDs
Gene nGD Krabbe NPC1 Sandhoff
Fold change (−/− vs. +/−) p value Fold change (−/− vs. +/−) p value Fold change (−/− vs. +/−) p value Fold change (−/− vs. +/−) p value
Inflammation
Gfap 6.8 ± 1.6 <0.005 2.6 ± 0.8 <0.05 2.1 ± 0.6 0.059 2 ± 0.5 <0.05
Adgre1 (F4/80) 6.6 ± 0.4 <0.001 3.9 ± 0.7 <0.005 3.6 ± 1.1 <0.05 2.7 ± 0.4 <0.05
Gpnmb 78.4 ± 15.6 <0.001 77.2 ± 45.4 <0.05 12.6 ± 4.9 <0.05 2.6 ± 0.4 <0.005
Tnf a 11.2 ± 2.5 <0.005 9.3 ± 5.12 <0.05 1.7 ± 0.3 <0.05 1.6 ± 0.2 <0.05
Il-1β 7.5 ± 4.6 <0.005 4.4 ± 1.0 <0.005 5.8 ± 1.4 <0.05 2.8 ± 0.1 <0.005
Ccl2 129.2 ± 46.3 <0.005 25.4 ± 16.1 <0.05 3.9 ± 1.2 <0.05 3.5 ± 1.5 <0.05
Ccl3 371.3 ± 131.7 <0.05 18.0 ± 9.3 <0.001 11.8 ± 3.5 <0.05 6.7 ± 1.3 <0.001
Ccl5 240 ± 19.3 <0.001 11.3 ± 2.2 <0.001 4.7 ± 1.2 <0.05 2 ± 0.3 <0.001
Il-10 1.8 ± 0.4 <0.05 2.0 ± 0.6 ns 0.9 ± 0.2 ns 1.1 ± 0.2 ns
Il-6 22.1 ± 7.0 <0.005 7.4 ± 3.1 <0.05 1.7 ± 0.8 ns 1.1 ± 0.3 ns
Anti-viral response
Ifnα 1.7 ± 0.8a ns 2.0 ± 1.3 ns 0.9 ± 0.5 ns 1.5 ± 0.7 ns
Ifnβ 3.9 ± 1.7 <0.05 2.1 ± 1.7 ns 1 ± 0.5 ns 1 ± 0.4 ns
Irf7 130.9 ± 18.4 <0.001 7.3 ± 2.9 <0.05 4.6 ± 0.8 <0.001 1.6 ± 0.2 <0.05
Usp18 104.4 ± 13.3 <0.001 11.2 ± 2.4 <0.001 7.1 ± 0.5 <0.001 1.6 ± 0.2 <0.05
Oas1b 22.6 ± 5.6 <0.001 5. 7 ± 2.1 <0.05 2.6 ± 1.2 ns 1.1 ± 0.4 ns
Eif2ak2 11.7 ± 1.1 <0.001 3.5 ± 1 <0.05 1.9 ± 0.3 <0.05 1.4 ± 0.1 <0.05
RIPK pathway
Rip1 2.3 ± 0.4 <0.005 2 ± 0.36 <0.05 1.4 ± 0.2 <0.05 0.9 ± 0.04 ns
Rip3 9.1 ± 0.9 <0.001 2.3 ± 0.27 <0.05 1.5 ± 0.2 <0.05 0.7 ± 0.1 ns
Mlkl 9.4 ± 1.8 <0.001 4.74 ± 1.46 <0.05 1.8 ± 0.2 0.00898 1.2 ± 0.3 ns
Results are expressed as fold change of −/− versus control mice and are means ± s.e.m. CT values were normalized to levels of HPRT. Genes that were elevated >2-fold
with a p value of <0.05 are in bold. nGD mice (Gbaflox/flox; nestin-Cre mice, 3 weeks of age, n = 4); Krabbe’s disease (Galc−/− mice, 5 weeks of age, n = 3); Niemann-Pick
type C1 disease mice (NPC1−/−), 10 weeks of age, n = 3–4; Sandhoff disease (HexB−/− mice) 17 weeks of age, n = 2–3
aIt should be noted that there is a significant difference in the extent of elevation of mRNA levels depending on whether a pathological area of the brain was
used compared to half cerebral hemispheres. For instance, Ifnα was elevated 2.1-fold in layer V of the cortex, but 1.7-fold in a cerebral hemisphere. However, even
when using whole cerebral hemispheres, it is apparent that the extent of the inflammatory response is much higher in nGD compared to the other LSDs
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of consistency in the age of the brain material used, and
in the age of animals, renders quantitative comparison
difficult. Nevertheless, some information can be gleaned
from such a comparison. For instance, in a gene micro-
array analysis using spinal cord tissue from 4-month-old
Sandhoff disease mice [51], 58 genes were up-regulated,
of which 32 are common to nGD, although only one of
these is involved in IFN signaling (Fig. 7 and Table 3). A
microarray analysis on Npc1−/− mouse brain at different
stages of disease severity [52] revealed up-regulation of
112 genes, of which 88 were also up-regulated in nGD,
and 9 of these are in the IFN signaling pathway. IFNβ
secretion and increased STAT levels were demonstrated
in cultured human NPC fibroblasts [53]. The similarity
of the lipids that accumulate in nGD (GlcCer/GlcSph),
Krabbe (galactosylsphingosine), and NPC (in which
small but significant amounts of GlcCer accumulate in
addition to the primary storage material, cholesterol)
suggest that more complex GSLs such as ganglioside
GM2, which accumulate in Sandhoff disease, cannot
trigger the IFN response, whereas the more simple GSLs
do trigger this response, although to a different extent.
We recently demonstrated a critical role for RIP3 in
nGD pathology [33], although we have so far not been able
to determine the precise mechanistic role of RIP3. Of some
interest is the observation that viral and bacterial patho-
gens induce programmed necrosis via a RIP3-dependent
cell death mechanism [54–57], which can involve type I
IFN [58]. Unlike RIP3, ablating the type 1 IFN response,
using the Ifnar1-deficient mouse, did not alleviate disease
symptoms in nGD mice, and moreover, mRNA levels of
Rip1 and Rip3 were essentially unaltered. In contrast,
expression of Mlkl, the key down-stream player to RIP1-
RIP3 in programmed necrosis, was significantly lower in
Ifnar1−/− mice, indicating that Mlkl is a novel ISG. We
would like to verify this by examining the phosphorylation
state of RIP3 and MLKL, but unfortunately, no commercial
antibodies against the phosphorylated forms of mouse
RIP3 and mouse MLKL are currently available [59].
At this stage, we do not know if activation of type I
IFN signaling in nGD brain is beneficial or detrimental.
The lack of benefit upon induction of nGD in Ifnar1−/−
mice is somewhat surprising and might be due to acti-
vation of a compensatory inflammatory mechanism
upon interfering with IFN signaling pathways; alterna-
tively, endogenous activation of proteins that block
interferon signaling, such as Usp18 (Fig. 4), might alle-
viate any beneficial effect of IFN. Usp18 is arguably the
ISG with the most important role in establishing and
maintaining long-term desensitization to type I IFN
signaling [30]. This desensitized state allows cells to
recover from IFN signaling, whereas dysregulation of
IFN production and signaling manifests in autoimmune
disorders such as systemic lupus erythematosus and
Sjögren’s syndrome [60]. Finally, we cannot exclude the
possibility that mice treated with CBE succumb to
systemic disease, rather than a disease of the CNS, and
therefore, amelioration of neurological disease might
not be sufficient to alleviate disease symptoms in the
case of the Ifnar1−/− mouse.
Fig. 6 Proposed mechanism by which type I IFN is activated in nGD. Left Induction of the IFN response in neurons upon GlcCer accumulation.
Elevated levels of GlcCer are sensed directly or indirectly by a PRR resulting in activation of the antiviral response and production of IFNα and IFNβ.
IFN is secreted from neurons and engages IFNAR in neighboring cells, i.e., microglia. Right Upon engagement, IFNAR activates phosphorylation,
dimerization, and nuclear translocation of STAT proteins, which subsequently induce the expression of ISGs, among them MLKL, which forms the
necrosome complex together with phosphorylated RIP3
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Methods
Mice
Gbaflox/flox; nestin-Cre mice were used as a genetic model
of nGD [21]. Gbaflox/flox mice were crossed with Gbaflox/wt;
nestin-Cre mice to generate Gbaflox/flox; nestin-Cre mice
(referred to as Gba−/− mice) and Gbaflox/wt; nestin-Cre
mice (referred to as Gba+/− mice), which served as healthy
controls since they do not show any overt pathology [22].
IFN-I receptor-deficient (Ifnar1−/−) mice [34] were back-
crossed with C57BL/6 mice to generate Ifnar1+/− mice.
Ifnar1+/− mice were crossed with Ifnar1−/− mice to
generate Ifnar1+/− and Ifnar1−/− littermates. Ifnar1+/− and
Ifnar1−/− mice were injected daily i.p. with 37.5 mg/kg
body weight CBE, an irreversible GCase inhibitor [36],
from 8 days of age. Ifnb1tm1Lky/J mice were obtained from
Jackson and were injected daily i.p. with 100 mg/kg body
weight CBE from 8 days of age. Ifnarflox/flox mice [61]
were crossed with CX3CR1-Cre mice [40] to generate
Ifnarflox/wt; CX3CR1-Cre mice. Ifnarflox/flox; CX3CR1-
Cre mice were crossed with Ifnarflox/flox mice to
generate Ifnarflox/flox; CX3CR1-Cre and Ifnarflox/flox
littermates. Ifnarflox/flox; CX3CR1-Cre and Ifnarflox/flox
mice were injected daily i.p. with 100 mg/kg body
weight CBE from 8 days of age. Mice deficient in the
β subunit of β-hexosaminidase A and B were used as
mouse model of Sandhoff disease [45]. Brains from a
mouse model of Krabbe’s disease [44], defective in β-
galactocerebrosidase (the Twitcher mouse), were
provided by Dr. Timothy M. Cox (University of
Cambridge). Brains from Niemann-Pick disease type
Table 3 Comparison of gene arrays for NPC1, Sandhoff, and nGD
Sandhoff [51] NPC [52] nGD
Tissue Spinal cord Brain VPM/VPL
Age/disease severity 4 months old
(late-symptomatic stage)





Analysis cut-off 2-fold 1.5-fold 1.5-fold
Number of up-regulated genes 58 112 907
Number (and percent) of up-regulated
genes common to nGD
32 (55.2 %) 88 (78.5 %)
Number (and percent) of IFN-related
genes among the up-regulated genes
1 (1.7 %) 9 (8 %) 49 (5.4 %)
Percentage of IFN-related gene out of
total of 145 IFN-related genes
0.70 % 6.20 % 33.80 %
Fig. 7 Gene changes in LSDs. Upper panel Venn diagram of differentially-expressed genes in spinal cord of Sandhoff disease, brain of NPC1 disease,
and the VPM/VPL of nGD. Lower panel Venn diagram of differentially expressed genes related to the type I IFN pathway to up-regulated genes in other
diseases. The enrichment IFN signaling lists were obtained from GSEA (REACTOME_INTERFERON_SIGNALING). Overlapping regions were drawn to scale
and the number of shared and unique genes listed. Overlap was visualized using BioVenn
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C1 mice, defective in the Npc1 gene [62], were
provided by Dr. Nick Platt (Oxford University).
Human brain tissue
A control human brain from an infant who died at
birth was provided by the University of Miami Brain
and Tissue Bank for Developmental Disorders. The
control brain was frozen within 6 and 26 h of death.
Brains from Gaucher patients were obtained postmor-
tem with informed consent between 7 and 22 h after
death [63]. After removal, brains were frozen on dry
ice.
Gene expression profiling microarray analysis
Mice were sacrificed and their brains removed and
placed on a Young Mouse Brain Slicer Matrix
(BSMYS001-1, Zivic instruments, Pittsburgh, PA, USA).
Single-edge razor blades were inserted into the matrix to
generate 1-mm coronal sections. Sections containing the
VPM/VPL were snap-frozen on dry ice and a 17-g
(1 mm diameter) blunt needle attached to a syringe was
used to remove the VPM/VPL; the cerebral cortex was
separated using a spatula. Each sample was placed in a
microcentrifuge tube, snap-frozen in liquid N2, and
stored at −80 °C.
Total RNA was isolated using the RNeasy Mini Kit
(QIAGEN GmbH, Hilden, Germany) according to
manufacturer’s instructions, which included DNase
treatment and addition of β-mercaptoethanol. A micro-
array experiment was performed on 100-ng RNA per
sample purified from the VPM/VPL region of Gba+/–
and Gba−/− mice at 14 days (n = 3) of age. Purified RNA
was reverse-transcribed and amplified using an Ambion
WT expression kit and labeled with an Affymetrix
GeneChip® WT Terminal Labeling kit. Labeled cDNA
was hybridized to Affymetrix Mouse Gene 1.0 microarrays
according to manufacturer’s instructions. Microarrays
were scanned using a GeneChip® scanner 30007G and
statistical analysis performed using Partek® Genomics
Suite software (Partek Inc., St. Louis, MI, USA). For each
age group, CEL files (containing raw expression measure-
ments) were imported to Partek GS. The data was proc-
essed and normalized using the RMA (Robust Multichip
Average) algorithm [64] with GC correction, and a three-
way ANOVA model was used to identify differentially
expressed genes; fold-changes were calculated. Analysis of
Gba gene probe sets verified that the mRNA expression of
Gba flanked exons [21] was reduced in Gba−/− samples.
Gene lists were created by filtering the genes based
on an absolute linear fold change ≥1.5, p ≤ 0.05, and
signal above background in at least one microarray
(log2 intensity ≥6) (Additional file 1: Table S1). The
gene lists were analyzed for enriched pathways using
GSEA (www.broadinstitute.org/gsea), Ontologizer (Elim
algorithm) [23], DAVID [65] against the KEGG pathways
database, and IPA (Ingenuity® Systems, www.ingenuity.-
com). The enrichment of the lists was tested against the
expressed genes (above background signal) when imple-
menting the Ontologizer tool. Microarray data were de-
posited in the Gene Expression Omnibus (GEO) database,
www.ncbi.nlm.nih.gov/geo (accession no. GSE46866). The
BioVenn tool (http://www.cmbi.ru.nl/cdd/biovenn/) [66]
was used to identify common and exclusively expressed
genes between groups.
qPCR
cDNA synthesis was performed using the Reverse-iT
First-Strand Synthesis Kit (Thermo Fisher Scientific,
Surrey, UK) using random decamers. cDNA products
were stored at −20 °C. qPCR was performed using
PerfeCTa SYBR Green FastMix (Quanta BioSciences,
Gaithersburg, MD, USA) and an ABI Prism 7300
Sequence Detection System (Applied Biosystems, Fos-
ter City, CA, USA). The primer concentration was
13 nM in a reaction volume of 20 μl and cDNA
equivalent to 2–20 ng of total RNA, or 300 ng for
Ifnb1 and Ifna2. Each reaction was performed in trip-
licate. The thermal cycling parameters were as fol-
lows: step 1, 95 °C for 10 min; step 2, 95 °C for 15 s,
60 °C for 30 s, and 68 °C for 30 s. Step 2 was re-
peated for 40 cycles and was followed by a dissoci-
ation step. Fold change in mRNA levels was
calculated using the comparative cycle threshold
method using TATA box binding protein (TBP) or
hypoxanthine phosphoribosyltransferase 1 (HPRT) for
normalization. p values were calculated using a two-
tailed, two-independent sample Student’s t test.
Primers for Ifnb1, Ifna2, Il-1β, and Il-10 were from
QIAGEN. Primers sequences are in Table 4.
ELISA
Frozen cerebral brain tissues were homogenized in
0.1 M phosphate buffer (PBS) supplemented with a
protease inhibitor cocktail (1:200, Sigma). Samples
were sonicated and centrifuged at 14,000gav for
10 min at 4 °C, and the supernatant was collected.
Protein was quantified using the BCA protein assay
reagent (Pierce Chemical Co., Rockford, Illinois,
USA). Homogenates containing ~3–4 mg of protein
were applied to a VeriKine™ mouse Interferon Alpha
ELISA kit (PBL Interferon Source, Piscataway, NJ,
USA), ~2 mg of protein were applied to Verikine-HS™
mouse Interferon Beta Elisa kit (PBL Interferon
Source), and 1 mg was applied to a VeriKine™ Human
Interferon Beta ELISA kit (PBL Interferon Source,
Piscataway, NJ, USA) according to manufacturer’s
guidelines.
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Immunohistochemistry
Brains were removed and immersion fixed in 2.5 %
paraformaldehyde in 0.1 M PBS, pH 7.4 for 2 days,
embedded in paraffin blocks, and 4-μm coronal sections
prepared on Superfrost + slides. Sections were deparaffinized
and rehydrated prior to further use. Antigen retrieval
was performed using 10 mM citric acid (pH 6.0) for
10 min at ~100 °C. Sections were blocked using 20 %
normal horse serum (NHS) (Vector, Burlingame, CA,
USA) and 0.3 % Triton X-100. Sections were incu-
bated with either rabbit antiphospho-Y690-Stat2 (1:50,
Abcam, Cambridge, MA), mouse anti-NeuN (1:50,
Chemicon, Temecula, CA, USA), rat anti-MAC2
(1:250, Cedarlane, Ontario, Canada), mouse anti-PKR
(1:100, Santa Cruz), rabbit anti-GFAP (1:100, Dako),
or with a goat anti-GFP antibody (Biotin, 1:100,
Abcam, Cambridge, MA). Antibody mixtures were diluted
in 2 % normal horse serum (NHS) containing 0.3 % Triton
X-100. Sections were incubated with the first antibodies
overnight at room temperature. For P-Stat2 detection,
sections were incubated with a biotinylated donkey anti-
rabbit secondary antibody (1:200, Jackson, West Grove,
PA, USA) and for PKR with a biotinylated donkey
antimouse secondary antibody (1:200, Jackson, West
Grove, PA, USA) for 2 h followed by Cy3-conjugated
streptavidin (1:200, Jackson) for 1 h. NeuN-stained
samples were incubated with a Cy2-conjugated don-
key antimouse antibody (1:200, Jackson ImmunoRe-
search), MAC2 with a Cy2-conjugated donkey antirat
antibody (1:200, Jackson ImmunoResearch), and GFAP
with a Cy2-conjugated donkey antirabbit antibody
(1:200, Jackson ImmunoResearch) for 1 h. Counter-
staining was performed with DAPI (Molecular Probes,
Eugene, OR, USA) (1:1000, 4 min), sections were
rinsed with PBS, mounted with Flouromount-G
(SouthernBiotech), and coverslipped.
Protein extraction and Western blotting
Homogenates were prepared as described [67]. Blots
were incubated with the following antibodies: mouse
anti-PKR (1:1,000, Santa Cruz), rat anti-MAC2 (1:1,000,
Cell Signaling), and a mouse anti-GAPDH (1:10,000,
Chemicon), followed by incubation with a horseradish
peroxidase-conjugated secondary antibody (antimouse,
Jackson ImmunoResearch). Bound antibodies were de-
tected using the SuperSignal West Pico chemilumines-
cent substrate (Thermo Scientific).
Conclusions
The type I IFN response appears to be a significant
player in the development of nGD pathology and pos-
sibly in other LSDs in which simple GSLs accumulate.
Our data support the developing notion that the IFN
signaling pathway (Fig. 6) plays a vital role during the
sterile inflammation that often occurs during chronic
neurodegenerative diseases in which neuroinflammation
is present.
Table 4 Primers used for qPCR
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